Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | ESR1 | P03372 | 3/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TYR | P14679 | 3/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572516 | 0.84 | L3MBTL1 (0.65) | L3MBTL1ESR1ESR2LCKNPC1 | |
| SCHEMBL9397888 | 0.82 | ESR1 (0.65) | L3MBTL1ESR1ESR2NPC1RAB9A | |
| SCHEMBL30674459 | 0.82 | L3MBTL1 (0.75) | L3MBTL1ESR1ESR2LCKNPC1 | |
| SCHEMBL10726700 | 0.82 | L3MBTL1 (0.75) | L3MBTL1ESR1ESR2LCKNPC1 | |
| SCHEMBL18906124 | 0.79 | LCK (0.59) | ESR1LCKTYRKDM4EHTT | |
| SCHEMBL4733137 | 0.78 | L3MBTL1 (1.00) | L3MBTL1ESR1ESR2NPC1RAB9A | |
| SCHEMBL9099369 | 0.78 | ESR1 (0.52) | L3MBTL1ESR1ESR2NPC1RAB9A | |
| SCHEMBL10397935 | 0.77 | L3MBTL1 (0.63) | L3MBTL1ESR1ESR2LCKNPC1 | |
| SCHEMBL4459400 | 0.77 | ESR1 (0.86) | L3MBTL1ESR1ESR2NPC1RAB9A | |
| SCHEMBL10397938 | 0.76 | L3MBTL1 (0.62) | L3MBTL1ESR1ESR2LCKNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167277-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, L.L.C. | 2008-07-10 | — | — | US | disclosed |
| US-20080167277-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, L.L.C. | 2008-07-10 | — | — | US | disclosed |
| EP-0809493-B1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | US HEALTH (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-0809493-A1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-12-03 | — | — | EP | disclosed |
| US-5610185-A | Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996025159-A1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167277-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | CYP24A1, VDR, CYP2R1 | L3MBTL1 3866/4885ESR1 2883/4885ESR2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.